Bausch+Lomb Results Presentation Deck
Solid Revenue Growth Driven by Performance in Key Franchises
3Q23 vs. 3Q22
+7% Revenue Growth Reported
+8% Revenue Growth CC ¹,3
Pharma
17%
Surgical
18%
$1,007 M Vision
Care
65%
BAUSCH+ LOMB
3Q23
Revenue
$187M 3023 Adj. EBITDA¹
-$14M Adj. EBITDA FX headwinds
Vision Care²
$648M
Surgical
+11%
Growth momentum in Lumify®,
Eye Vitamins, Daily SiHy, Artelac®
Improving lens order processing
at Lynchburg distribution facility
3Q23 REPORTED REVENUE
$185M
3Q23 CONSTANT CURRENCY REVENUE GROWTH ¹
Pharmaceuticals ²
+6%
Continuing to transition
portfolio to premium IOLS
Delivering consistent level of
supply remains a focus area
$174M
+1%
Strong early Miebo launch,
closed Xiidra acquisition
Growth in VyzultaⓇ and Intl. Pharma,
offset by supply impact on
mature brands
1. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported
results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products..
The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
3. Constant currency.
5View entire presentation